Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Stem Cell Research

Background:

• The Hedgehog/Glioma-associated oncogene homolog (HH/GLI) signaling pathway is vital for cancer stem cell (CSC) self-renewal, driving tumor growth, metastasis, and drug resistance.
• Targeting CSC pathways, including HH/GLI, alongside conventional treatments is a critical unmet medical need.
• Pharmacological inhibition of HH/GLI signaling offers a promising strategy to eliminate CSCs.

Purpose of the Study:

• To review the mechanisms of resistance to Smoothened (SMO) inhibitors, a key therapeutic target in the HH/GLI pathway.
• To discuss novel, rationale-based approaches to overcome SMO inhibitor resistance and improve CSC eradication.
• To highlight the clinical need for effective anti-HH/GLI therapies against malignant CSCs.

Main Methods:

• Review of existing literature on HH/GLI signaling, CSC biology, and SMO inhibitor resistance.
• Analysis of genetic and molecular mechanisms contributing to de novo and acquired resistance.
• Exploration of emerging therapeutic strategies targeting GLI factors and related signaling pathways.

Main Results:

• SMO inhibitors show efficacy in certain cancers but face significant limitations due to resistance mechanisms.
• Resistance arises from genetic alterations in HH pathway components and noncanonical activation of GLI transcription factors.
• Novel approaches include targeting GLI enzymatic modifiers, directly inhibiting GLI, and disrupting synergistic oncogenic crosstalk.

Conclusions:

• Overcoming SMO inhibitor resistance is essential for effective CSC eradication and improved cancer therapy outcomes.
• Targeting GLI activity and its regulatory networks presents promising avenues for next-generation anti-HH/GLI therapies.
• Developing combination strategies that address resistance mechanisms will be key to realizing the full therapeutic potential of targeting HH/GLI signaling in cancer.